In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Prevalence of prognostic factors in pulmonary hypertension

Session Poster session 3

Speaker Adrian Lescano

Congress : Heart Failure 2017

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Poster Session
  • FP Number : P1964

Authors : A Lescano (Buenos Aires,AR), H Santa Maria (Buenos Aires,AR), A Lavalle Cobos (Buenos Aires,AR), D Crippa (Buenos Aires,AR), N Gonzalez (Buenos Aires,AR), A Ferro (Buenos Aires,AR), G Damianich (Buenos Aires,AR), G Romero (Buenos Aires,AR), I Constantin (Buenos Aires,AR), I Fernandez (Buenos Aires,AR), E Besmalinovich (Buenos Aires,AR), V Daru (Buenos Aires,AR), M Gonzalez (Buenos Aires,AR), H Grancelli (Buenos Aires,AR)

Authors:
A Lescano1 , H Santa Maria1 , A Lavalle Cobos1 , D Crippa1 , N Gonzalez1 , A Ferro1 , G Damianich1 , G Romero1 , I Constantin1 , I Fernandez1 , E Besmalinovich1 , V Daru1 , M Gonzalez1 , H Grancelli1 , 1Finochietto Clinic - Buenos Aires - Argentina ,

Citation:
European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 497

Pulmonary hypertension (PH) is a multi-factorial condition associated with high morbidity and mortality. It requires for its diagnosis and treatment a multidisciplinary approach.  In the past decades there have been many advances in the epidemiological, pathophysiological and therapeutic knowledge of the disease. However, there is little information available regarding clinical and prognostic factors in patients diagnosed with PH in Latin America. 
Pourpose: Determine the prevalence and clinical characteristics of adverse prognostic factors in a population with recent diagnosis of PH. 

Methods:  Patients with recent diagnosis of PH (< 7 days) confirmed  by right heart catheterization, with a mean pulmonary-artery pressure (MPAP) =  25 mm Hg (using a Swan Ganz Catheter) from three heart failure and pulmonary hypertension services were analyzed between March 2012 and December 2016. According to the recommendations of international guides, the following data were recorded: Personal data, PH group (G), clinical features: symptoms, functional class FC. Direct hemodynamic parameters: pulmonary pressures (PP), wedge pressure (WP), right atrium pressure (RA) and cardiac index (CI). Functional: 6 minute walk (6MW) test  distance. Echocardiographic variables: right ventricle systolic function (RVSF), tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary pressure and presence of pericardial effusion (PE).  Data obtained were analyzed with BioEstat 5.3 program. Adverse prognosis factors identified were: history of heart failure (HF), syncope, advance functional class (III-IV), performance in the 6MW test < 350 m, presence of PE, TAPSE =15¸ RA = 12  e CI = 2,2. 
Results:  Multicenter, observational, descriptive, consecutive and prospective study. 107 patients where included. 74% women. Mean age was 58,8 (±19) years, 33% = 70. The mean delay in diagnosis was 24 months after the first sign or symptom recorded. PH group distribution: GI 63%, GII15%, GIII9%, GIV6% and GV6%. FC of presentation: I4%, II 40%, III34% and IV20%. History of HF in 72%, syncope in 23%. 6MW mean distance walked was 320 (±148) meters, 47 % performed = 350 meters. RHC: MPAP 48.3 (±16) mmHg, RAP 9.7 mmHG (±5,2) and = 15 mmHg  27%; CI 2,78 litres/min/mt2 (= 2,2 23%). Ecocardiographic data show: 79% impaired FSVD (42% slight, 18% moderate and 19% severe). Mean TAPSE 17.8 (±4) mm, = 15 mm  37 % and PE in 25%.
Conclusions: In our population with confirmed pulmonary hypertension, with a predominance of group I, we had a high presentation in over 70 years of age. At diagnosis time a high number of patients present adverse prognosis factors.  This findings remark the need to use early diagnosis and therapeutic strategies.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are